Tag : FEV1

CONFERENCE UPDATE

Improving asthma remission with benralizumab in real-world asthma patients in the US: Results from the ZEPHYR-4 study
The anti-interleukin-5 receptor α (anti-IL-5α) monoclonal antibody (mAb), benralizumab, had been approved for the treatment of severe eosinophilic asthma offering significant improvements in exacerbation rates, maintenance oral corticosteroid (mOCS) use, and other asthma outcomes in phase 3 clinical trials. Although benralizumab has achieved asthma remission in clinical trials and non-United States (US) populations, real-world data within the US assessing similar outcomes remained limited.